Obviously to much to handle for yourself per your deletion. Just remember if you are going to throw crud against the wall and hope it sticks be ready to be called out when it slips to the floor and someone steps in it.
You deleted it because I embarrassed you about your lack of knowledge regarding biotech companies and stocks. Simply as that. I clearly gave you an explanation on why Amrn can't pursue a combo pill, how BP companies think regarding smalltime biotechs and why what is going on currently with amrn's pps has little to do with the shorts. Now run along and take your ball with you!
Again I will repeat my earlier post that got deleted because you deleted your post probably because you know I was right. I am not angry however I have zero tolerance for someone like you that doesn't have a clue what you are talking about blaming shorts and starting basless threads about combo pills that will never happen. When you ask for an explanation I give it and you respond immaturely like RAF when you don't like a truthful response that calls out your lack of intelligence regarding Amrn.
Not angered at all just have zero patience for posters like yourself who don't have a clue what you are talking about and just throw crud against the wall and hope it sticks.
Thanks for going back to blaming the shorts. Something you are good at but of course are way off base about. Stick to what you know......but if that was the case you wouldn't post at all!
Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin
Is that really your only rebuttal after I clearly laid out how this works? Please return to your shorts are toast posts. You are clueless!
It's clear that you don't understand how the market or biotech companies work or think. Today's biotech markets go after a MS drug because there is no cure and it would be a multi billion dollar industry. The market is saturated with cardio drugs. If Biib hits on its ms drug the sky is the limit for that company. BTW I forgot to mention the reason Biib said it is in the acusition market is because of the depressed market and values out there. If you think BP is going to be amrn's friend think again. They will get it on their terms.
Timing is also a consideration as well. The market and most bio's are in tough shape but there are exceptions if you look at a company like Biib who hit it out of the park last quarter and is on record as saying they are looking at aqusitons. Before everyone gets excited Amrn would not be on their radar. They are looking at bigger things like MS.
BP will still get this on there terms. They may even let Amrn try to sell the expanded label on their own for a while and make them sweat if reduce it passes. Again these pie in the sky projections never come to fruition. It will be a reasonable offer but not the $30 that some predict.
Your theory makes sense. It's why I have been able to make 3 successful trades even off of this downturn.there are many longs that are Serverky underwater from the first go around. Hopefully they averaged down along the way. I still don't like this market so my reduce it play will wait.
For the same reason Amrn never got bought out up to this point. BP always lets the smalltime biotechs do all the heavy lifting. Run the trials have the burden of paying for the studies. A lot can go wrong along the way. BP didn't get to where they were by being stupid. They are more of an aqusiton company then a R&D company. Like I said this is all a mute point as Amrn would never be in a position to do this. Again as my mantra has been all alone this is about reduce it or bust'
Oh contrare morfare. Yes I was here back in the day before we all knew how this stock and company worked. It was well documented by the old regime here that I was well ahead of the curve and got out of this stock well before it tanked below a dollar. Never had anything close to $12 shares well before my time. This ticker has been very predictable over the past few trading seasons. I have said all along this latest carnage is market related and small bio's like amrn take it in the kister harder. You say this ticker moves on news? Not lately or certainy not what posters here consider news!